Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Tiziana Life Sciences, a clinical-stage biotechnology firm specializing in immunomodulation therapies, is set to present at the upcoming Jefferies London Healthcare Conference on November 19, 2025. The presentation, led by CEO Ivor Elrifi and COO/CFO Keeren Shah, will showcase the company’s innovative pipeline and highlight significant clinical milestones. Central to the discussion will be Tiziana's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody currently under development for neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (SPMS), Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS).

Foralumab stands out in the biopharmaceutical landscape as the only fully human anti-CD3 monoclonal antibody being studied with intranasal delivery, a method that has the potential for enhanced efficacy and safety compared to traditional intravenous routes. Encouraging results have been reported from their open-label Expanded Access Program, where all 14 patients with non-active SPMS experienced either an improvement or stability in their condition within six months of treatment. Additionally, foralumab is undergoing investigation in a Phase 2a clinical trial for the same patient population.

The Jefferies London Healthcare Conference is recognized as a key platform for attracting leading global healthcare firms and investors, underlining Tiziana's increasing visibility and commitment to addressing high unmet medical needs in the neurology field. The company's forward-thinking approach to drug delivery and its promising clinical data position it for a pivotal role in the evolving biotechnology landscape. Interested investors can arrange one-on-one meetings with Tiziana's management during the conference. For more details, visit Tiziana Life Sciences’ official website.

Tiziana Life Sciences (Nasdaq: TLSA) has positioned itself at the forefront of biotechnology innovation with its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody aimed at tackling neurodegenerative diseases. With a spotlight on the imminent presentation at the Jefferies London Healthcare Conference, investors should closely monitor this event as it serves as a critical platform for the company to demonstrate its clinical milestones and pipeline potential.

Foralumab's unique delivery method, administered intranasally, could reshape treatment paradigms for conditions such as non-active secondary progressive multiple sclerosis (SPMS) and Alzheimer's disease. The recent clinical results, where 14 patients showed either stability or improvement in disease, bolster the thesis that Tiziana's approach could offer significant clinical benefits over existing therapies, which often rely on intravenous delivery.

Given the heightened interest in innovative therapies for high unmet medical needs, Tiziana's participation at such a prestigious event could enhance investor visibility and engagement. The commitment of Tiziana’s leadership to one-on-one meetings during the conference further emphasizes their proactive approach in cultivating investor relations.

From a market perspective, Tiziana appears to be at an inflection point. Analysts should be attentively watching data from ongoing clinical trials to gauge foralumab's efficacy and safety profile as these will be pivotal in shaping future funding, partnerships, and stock performance. If Tiziana continues to produce positive outcomes, investor sentiment could remain bullish, potentially establishing the company as a significant player in the biotechnology sector.

In summary, Tiziana Life Sciences is poised for a notable presence at the Jefferies Conference. Stakeholders would benefit from tracking the outcomes of this engagement and subsequent clinical trial data that could validate the company's innovative therapeutic pipeline.